Vanda Pharmaceuticals Inc. (VNDA) SEC Filings & Earnings Calls

Pharmaceutical tariff exposure

“On April 2, 2026, the President issued a proclamation ... imposing a 100% ad valorem tariff on imports of patented pharmaceutical products and associated pharmaceutical ingredients, including APIs.” · word for word

HETLIOZ generic erosion

“HETLIOZ ® net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S.” · word for word

Cash burn rate

“Cash and marketable securities declined from $263.8M at Dec 2025 to $170.0M at June 2026.”

HETLIOZ revenue decline of 66% YoY indicates significant market loss, possibly due to generic competition or loss of exclusivity.

“HETLIOZ net product sales were $5.6 million in Q2 2026, down 66% year-over-year.”

Operating losses increasing: loss before income taxes widened to $62.4M from $34.9M, reflecting high investment in launches and pipeline.

“Loss before income taxes was $62.4 million in Q2 2026 compared with $34.9 million in Q2 2025.” · word for word

Cash burn: Cash decreased by $32.3M in Q2 2026; runway only through end of 2027, requiring successful product launches or financing.

“Cash totaled $170.0 million as of June 30, 2026, representing a decrease of $32.3 million in Q2 2026.” · word for word

HETLIOZ generic erosion

“HETLIOZ ® net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S.” · word for word

Cash burn

“As of March 31, 2026, our total cash and cash equivalents and marketable securities were $202.3 million compared to $263.8 million at December 31, 2025.” · word for word

Medicare Part D pricing pressure

“The Medicare Part D benefit redesign has resulted in overall higher discounts for our Medicare payor segment relative to the previous Medicare Part D prescription drug coverage gap discount program.” · word for word

Valuation allowance on deferred tax assets

“we have concluded that it is not more likely than not that substantially all of our deferred tax assets are realizable in future periods and maintained a valuation allowance against all net deferred tax assets” · word for word

HETLIOZ revenue decline of 24% year-over-year, indicating potential market share loss or generic competition

“HETLIOZ net product sales were $15.9 million, down 24% year-over-year” · word for word

Cash burn of $61.5M in Q1, including $10M milestone payment, may pressure runway if not offset by revenue growth

“Cash totaled $202.3 million as of March 31, 2026, representing a decrease of $61.5 million in Q1 2026” · word for word

Concentrated Product Portfolio

“The filing references Fanapt and Hetlioz as key products, indicating reliance on a limited number of drugs.”

Related Party Transactions / Governance Risk

“Three family members of the CEO are employed by the company with total cash compensation exceeding $1.35 million in 2025.”

Key Person Dependency

“CEO Mihael Polymeropoulos has been granted 3,845,000 shares under the 2016 Plan, indicating significant reliance on his leadership.”

Key executive departure without immediate replacement may create governance vacuum.

“Resignation of General Counsel and Secretary effective April 10, 2026.”

No financial details or guidance provided; launch timing and revenue potential remain uncertain.

“No revenue, pricing, or volume data disclosed.”

Commercial execution risk for new product launch.

“Market acceptance and competition risks.”

Valuation allowance of $113.7M against deferred tax assets (non-cash charge).

“The provision for income taxes in the fourth quarter of 2025 includes the impact of the recording of a valuation allowance of $113.7 million against all of Vanda’s deferred tax assets” · word for word

HETLIOZ sales declining; reliance on Fanapt growth.

“HETLIOZ net product sales were $16.4 million in the fourth quarter of 2025, an 18% decrease” · word for word

Regulatory risk: FDA rejection of HETLIOZ sNDA for jet lag disorder

“FDA letter stating sNDA cannot be approved in its current form”

Regulatory risk reduced; clinical hold lifted but development and approval risks remain.

“partial clinical hold lifted; further clinical trials and FDA approval still required”

Regulatory outcome for tradipitant uncertain; no approval or financial impact disclosed.

“Regulatory update on tradipitant for motion sickness; no approval or financial impact disclosed.”

Generic competition for HETLIOZ

“HETLIOZ net product sales may decline in future periods, potentially significantly, related to continued generic competition in the U.S.” · word for word

Medicare Part D redesign revenue pressure

“Revenues may decline in future periods, potentially significantly, as a result of the Medicare Part D program benefit redesign.” · word for word

Elevated inventory destocking at specialty pharmacies

“HETLIOZ net product sales may reflect lower unit sales as a result of the reduction of elevated levels at specialty pharmacy customers or may be variable depending on when specialty pharmacy customers need to purchase again.” · word for word

High SG&A and R&D spending pressure on profitability

“Selling, general and administrative expenses may increase in future periods as a result of the ongoing commercial launches.” · word for word

Widening net loss due to increased operating expenses.

“Net loss increased from $5.3M to $22.6M YoY.”

Cash burn: Cash decreased by $31.8M from June 30, 2025.

“Cash decreased to $293.8M from $325.6M.”